tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Malaria'

Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility

Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility

LOGAN, UT – December 22, 2014 – Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced completion of the Company’s production facility in South Africa. Further, the Company announced that samples from the first batch of Phytofare® Catechin Complex, which is derived from green tea, are being delivered to testing facilities for final profiling which will take place once vendors return from holiday. ...

Read More →
0

Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market

Plandai Biotechnology, Inc. Involved in Numerous Clinical Trials as Company Prepares Products for Market

Written by ι Stock Market Media Group Staff — October 3, 2013

Plandaí Biotechnology, Inc. (OTCQB: PLPL) has several clinical trials already underway, and a host of others scheduled to commence in the company months as the company feverishly prepares products for market in its transition from solely a research and development firm to a biotech with products in the marketplace.  Plandaí has stated its goal is to have most of the trials it has commissioned completed by the end of March 2014 ...

Read More →
0

Buy Rating and New Report Issued for Plandai Biotechnology, Inc.

Buy Rating and New Report Issued for Plandai Biotechnology, Inc.

September 23, 2013

Stock Market Media Group, a research and content development investor relations firm, has released its 3rd Quarter report and issued a Speculative Buy Rating on Plandaí Biotechnology, Inc. (OTCQB: PLPL).  The report: Plandaí Biotechnology, Inc. – From R&D to Market, is the first in a series of reports that will follow Plandaí as it transitions from a biotech solely engaged in research and development to a company launching products into the marketplace.

Read the Plandaí Report at www.stockmarketmediagroup.com/reports.

In ...

Read More →
0

Plandai Biotechnology, Inc. is Taking on the Malaria Parasite and Winning

Plandai Biotechnology, Inc. is Taking on the Malaria Parasite and Winning

Written by ι Stock Market Media Group Staff — June 6, 2013

Plandaí Biotechnology, Inc. (OTCQB: PLPL) recently put one of the company’s highly bioavailable products to work in a study to prove it can kill a deadly parasite.  It was Plandaí’s Phytofare™ Catechin Complex, and it proved it can, in fact, be effective in killing the parasite.  This is big news for a company that plans on using its products as an antimalarial drug target in the war on this worldwide disease ...

Read More →
0

Plandaí Biotechnology, Inc. New Products to Hit the Market with Higher Absorption Rate

Plandaí Biotechnology, Inc. New Products to Hit the Market with Higher Absorption Rate

Written by ι Stock Market Media Group Staff — May 14, 2013

In a series of articles Stock Market Media Group, a research and content development investment relations firm, will lay out Plandaí Biotechnology, Inc.’s (OTCQB: PLPL) three new products all being individually labeled and branded under the Phytofare™ name.  In addition to the products, the patented extraction process the company will use to bring customers its healthy lineup of extracts will also be highlighted.  This installment will focus on the first of ...

Read More →
0
ContactUs.com